Evidence map›Paper›PMID 29031928›Full record

ArticleAnaerobe2017

The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Yongrong Zhang, Zhiyong Yang, Si Gao, Therwa Hamza, Harris G Yfantis, Michael Lipsky, Hanping Feng

Open access · greenAbstract read
In one paragraph

Article in Anaerobe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. The Comparative Characterization of a HypervirulentInternational journal of molecular sciences · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yongrong ZhangDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
Zhiyong YangDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
Si GaoDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
Therwa HamzaDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
Harris G YfantisDepartment of Pathology and Laboratory Medicine, VAMHCS, University of Maryland School of Medicine, Baltimore, MD, USA.
Michael LipskyDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Hanping FengDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA. Electronic address: HFeng@umaryland.edu.
University of Maryland, Baltimore · US

Funding

Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
A Novel Humanized Tetra-specific Antibody against Clostridium difficile InfectionR01AI132207 · NIAID · FZATA, INC. · PI FENG, HANPING, YANG, ZHIYONG · 2017 to 2022
$8.1M
Development of Vaccines against Clostridium difficile InfectionR01AI088748 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FENG, HANPING, TZIPORI, SAUL R · 2010 to 2014
$3.1M
Epithelium, dendritic cells, and Clostridium difficile associated colitisR01DK084509 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI FENG, HANPING · 2010 to 2014
$1.7M
Toxemia and systemic disease in Clostridium difficile infectionR56AI099458 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FENG, HANPING · 2013 to 2013
$388k
A Yeast based Immunotherapy against Clostridium difficile InfectionR43AI129044 · NIAID · FZATA, INC. · PI YANG, ZHIYONG · 2017 to 2017
$225k
NIAID NIH HHS R01 AI088748NIAID NIH HHS R01 AI132207NIAID NIH HHS R43 AI129044NIAID NIH HHS R56 AI099458NIAID NIH HHS U19 AI109776NIDDK NIH HHS R01 DK084509
6 · The paper itself

Abstract

Most pathogenic Clostridium difficile produce two major exotoxins TcdA and TcdB, in the absence of which the bacterium is non-pathogenic. While it is important to investigate the role of each toxin in the pathogenesis of C. difficile infection (CDI) using isogenic strains, it is impossible to precisely control the expression levels of individual toxins and exclude bacterial factors that may contribute to the toxins' effects during infection. In this study, we utilized an acute intestinal disease model by injecting purified toxins directly into mouse cecum after a midline laparotomy. We evaluated the physical condition of mice by clinical score and survival, and the intestinal tissue damage and inflammation by histology. Depending on the dose of the toxins, mice developed mild to severe colitis, experienced diarrhea or rapidly died. We found that both purified TcdA and TcdB were able to induce clinical disease, intestinal inflammation, and tissue damage that resembled CDI. TcdA was significantly faster in inducing intestinal inflammation and tissue damage, and was approximately five times more potent than TcdB in terms of inducing severe gut disease and death outcomes in mice. Moreover, we found that the two toxins had significant synergistic effects on disease induction. Comparison of the in vivo toxicity of TcdB from clinical strains revealed that TcdB from an epidemic RT 027 strain was more toxic than the others. Our study thus demonstrates that both TcdA and TcdB, independent of other factors from C. difficile bacterium, are able to cause disease that resembles CDI and highlights the importance of targeting both toxins for vaccines and therapeutics against the disease.

Indexed as

AnimalsBacterial ProteinsBacterial ToxinsBiomarkersCecumClostridioides difficileDisease Models, AnimalEnterocolitis, PseudomembranousEnterotoxinsHumansMicePhosphorylationBacterial ProteinsBacterial ToxinsBiomarkersEnterotoxinstcdA protein, Clostridium difficiletoxB protein, Clostridium difficileCecumClostridium difficilePathogenesisToxin AToxin B

Identifiers

PMID29031928
PMCPMC5792825
OpenAlexW2761528488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.